Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00623636 · ClinicalTrials.gov registry record · Phase 3
Phase 3 Study of MAP0004 in Adult Migraineurs
A Phase 3 study of Migraine Disorders, sponsored by Allergan.
- Completed
- Registry status
- Phase 3
- Development phase
- 902
- Enrollment target
- 1
- Study location
NCT00623636: Completed Phase 3 study of Migraine Disorders, sponsored by Allergan.
NCT00623636 is a Phase 3 study of Migraine Disorders that has completed, run by Allergan. The registered enrollment target is 902 participants, above the 272-participant average among 21 other Migraine Disorders trials with a reported enrollment target (232% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00623636, a Phase 3 study of Migraine Disorders, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 902 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a randomized, double blind, placebo controlled, parallel group study of MAP0004 in adult migraineurs. Subjects will self administer study drug in the outpatient setting.
Primary Outcome
Pain relief at 2 hours was defined as change in rating from severe or moderate (score 3 or 2) to a rating of none or mild (score 0 or 1) at the 2-hour time point and no usage of rescue medications from the time of first dose to 2 hours. The 4-point scale from the International Headache Society was used: 0 = none; 1 = mild symptom, not interfering with normal daily activities; 2 = moderate symptom, causing some restriction to normal activities; 3 = severe, leading to inability to perform daily
Conditions Studied
Interventions
- DRUG Placebo
- DRUG MAP0004
Study Locations (1)
Washington
- Swedish Pain and Headache Clinic - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 902 participants |
| Start Date | 2008-07 |
| Est. Completion | 2011-01 |
| Phase | Phase 3 |
What the finished NCT00623636 record still lists
NCT00623636 is an interventional study that assigns participants to a tested intervention. The registered 902 participants enrollment target is mid-sized for trials with a published cap, above the 272-participant average among 21 other Migraine Disorders trials with a reported enrollment target (232% higher).
The record links to 1 condition, with Migraine Disorders appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00623636 reports a single indexed study location in Washington.
Frequently Asked Questions
What is clinical trial NCT00623636 about?
NCT00623636 is a clinical study titled "Phase 3 Study of MAP0004 in Adult Migraineurs". This is a randomized, double blind, placebo controlled, parallel group study of MAP0004 in adult migraineurs. Subjects will self administer study drug in the outpatient setting.
What is the current status of trial NCT00623636?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 902 participants. The study started on 2008-07. Estimated completion is 2011-01.
What conditions does trial NCT00623636 study?
This clinical trial studies the following conditions: Migraine Disorders.
What interventions are being tested in trial NCT00623636?
The interventions under investigation include: Placebo (DRUG), MAP0004 (DRUG).
Who is sponsoring clinical trial NCT00623636?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00623636 being conducted?
This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Migraine Disorders
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00623636's enrollment target sits among peer trials
902 1st of 21 higher than 21 of 21 other Migraine Disorders trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Migraine Disorders trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Multicenter Assessment of ALD403 in Frequent Episodic Migraine
COMPLETED · Phase 3
-
Long-Term Safety of Treximet (Sumatriptan/Naproxen Sodium) for Migraine in Adolescents
COMPLETED · Phase 3
-
Study Of Treximet, Formerly Known as Trexima, In The Acute Treatment Of Multiple Migraine Attacks
COMPLETED · Phase 3
-
Treximet (Sumatriptan/Naproxen Sodium), Formerly Known as TREXIMA, for Menstrual Migraine in Women With Dysmenorrhea
COMPLETED · Phase 3
-
TREXIMET® Versus Butalbital-containing Combination Medications for the Acute Treatment of Migraine in Adults
COMPLETED · Phase 3
-
Migraine Manager (R01)
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05769777 · 901 participants · Phase 2
Open Label, Long-term Study Evaluating Safety and Efficacy of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis
- NCT02352116 · 900 participants · NA
Evaluation of Post-PACU Pain Management in Pediatric Surgery
- NCT02414347 · 900 participants
F 18 T807 Tau PET Imaging of Alzheimer's Disease
- NCT02670408 · 900 participants
Diagnostic and Therapeutic Applications of Microarrays in Heart Transplantation
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia